Proactive Research Analyst Daniel Appiah speaks to Thomas Warner at the London Studio after publishing a new research note on Oxford Cannabinoid Technology Holdings PLC. The pharmaceutical group announced on 27 July that it has commenced its phase I clinical trial for lead drug candidate, OCT461201, marking the administration of the first human dose. Appiah describes the news as a "major achievement" for Oxford Cannabinoid Technologies, highlighting its transformation from a development company into being a clinical company He also gives an overview of other recent news from the business. For more details, read Daniel's full report by clicking the link provided.
Proactive UK Ltd
+44 20 7989 0813
View source version on newsdirect.com: https://newsdirect.com/news/oxford-cannabinoid-technologies-first-dosing-a-major-achievement-proactive-research-analyst-633512101
Oxford Cannabinoid Technologies Holdings PLC
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Daily Scotland News journalist was involved in the writing and production of this article.